Results 201 to 210 of about 78,184 (307)

BTK Gene Mutation [PDF]

, 2020
openaire   +1 more source

Fatal Non‐Hepatic Hyperammonemia Post‐Glofitamab: Ureaplasma and Genetic Susceptibility: A Case Report

Immunity, Inflammation and Disease, Volume 14, Issue 4, April 2026.
ABSTRACT Background Although primarily reported in solid organ transplant recipients and patients undergoing chimeric antigen receptor T‐cell immunotherapy (CAR‐T), non‐hepatic hyperammonemia (NHHA) is a rare but lethal complication in the broader context of post‐ chemo‐immunotherapy hematologic malignancies.
Yinshan Wu, Xiuliu Guo, Xiaoling Wang, Feng Guo   +3 more
wiley   +1 more source

Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations. [PDF]

J Transl Med
Lu C, Chen Q, Shen Y, Chen M, Xie Y, Wang C, Yu L.   +6 more
europepmc   +1 more source

Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction Overweight and obesity are increasing rapidly in most countries. Underweight body mass index (BMI), though much less common, is also associated with adverse health outcomes. There is poor understanding of the implications of BMI in lymphoma patients.
Serif Sungur, Yao Yao, Cameron Wellard, Eliza Chung, Susan Morgan, Denise Lee, Geoffrey Chong, Chan Y. Cheah, Tasneem Rizvi, Eliza A. Hawkes, Zoe K. McQuilten, Erica M. Wood, Nada Hamad, Tasman Armytage, Anna M. Johnston   +14 more
wiley   +1 more source

Discovery of Covalent Ligands with AlphaFold3. [PDF]

J Am Chem Soc
Shamir Y, Gabizon R, Rogel A, Lin DY, Andreotti AH, London N.   +5 more
europepmc   +1 more source

Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction Marginal zone lymphoma (MZL) is an indolent yet incurable B‐cell malignancy in which targeted agents such as BTK and PI3K inhibitors frequently fail due to resistance or toxicity. Antimicrobial peptides (AMPs), evolutionarily conserved effectors of innate immunity, possess selective cytotoxicity against malignant cells by ...
Filippo Spriano, Alberto J. Arribas, Fangwen Zhang, Elisa Civanelli, Maria Luisa Mangoni, Francesco Buonocore, Francesco Bertoni   +6 more
wiley   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

Evidence and Equity Gaps in Clinical Care of Chronic Lymphocytic Leukaemia in Portugal: A Real‐World, Multicentre, Cohort Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Objectives Targeted therapies have markedly improved outcomes in chronic lymphocytic leukaemia (CLL), particularly among patients with TP53 alterations and unmutated IGHV. However, real‐world studies report persistent inequalities in access to optimal care.
Susana Esteves, Inês Coelho, José Carda, Sara Duarte, Inês Carvalhais, Daniela Alves, Rita Coutinho, Maria Gomes da Silva   +7 more
wiley   +1 more source

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia. [PDF]

Curr Hematol Malig Rep
Benrashid S, Woyach JA.
europepmc   +1 more source

Mechanisms of resistance to bruton's tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways. [PDF]

Ann Hematol
Dong X, Tang S, Chen M, Chen Q, Wang Y, Shi Y, Deng Y, Chen Y, He Z, Yu L, Wang C.   +10 more
europepmc   +1 more source